Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011 Review on JAK2 (janus kinase 2), with data on DNA, on the protein encoded, and where the gene is implicated.
openaire +1 more source
T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities
Advanced Science, EarlyView.T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu +7 more
wiley +1 more source
JAK inhibitors: a new choice for diabetes mellitus?
Diabetology & Metabolic SyndromeAltered tyrosine kinase signaling is associated with a variety of diseases. Tyrosine kinases can be classified into two groups: receptor type and nonreceptor type. Nonreceptor-type tyrosine kinases are subdivided into Janus kinases (JAKs), focal adhesion
Mengjun Zhou, Qi Shen, Bo Li
doaj +1 more source
Mechanistic Insights into Regulation of JAK2 Tyrosine Kinase
Frontiers in Endocrinology, 2018 JAK2 is a member of the Janus kinase (JAKs) family of non-receptor protein tyrosine kinases, which includes JAK1–3 and TYK2. JAKs serve as the cytoplasmic signaling components of cytokine receptors and are activated through cytokine-mediated trans ...
Stevan R. Hubbard
doaj +1 more source
Targeting kinases with anilinopyrimidines: Discovery of N-phenyl-N'-[4-(pyrimidin-4-ylamino)phenyl]urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily [PDF]
, 2015 Kinase inhibitors are attractive drugs/drug candidates for the treatment of cancer. The most recent literature has highlighted the importance of multi target kinase inhibitors, although a correct balance between specificity and non-specificity is ...
Chilin, Adriana +5 more
core +2 more sources
Oral spleen tyrosine kinase/Janus Kinase inhibitor gusacitinib for the treatment of chronic hand eczema: Results of a randomized phase 2 study [PDF]
, 2023 Pablo A. Jimenez +9 more
openalex +1 more source
Cytokine pathways driving diverse tissue pathologies in rheumatoid arthritis
Arthritis &Rheumatology, Accepted Article.Rheumatoid arthritis is a complex systemic disorder characterised primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease e.g. of the lung with potentially devastating clinical consequences.
Aurelie Najm +2 more
wiley +1 more source
Cardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: systematic review and network meta-analysis [PDF]
, 2023 Qiang‐hua Wei +7 more
openalex +1 more source
Janus kinase inhibitors for alopecia areata: a review of clinical data
Frontiers in ImmunologyAlopecia areata (AA) is an autoimmune disease characterized by inflammatory and non-scarring hair loss, mediated by CD8+ T cells and primarily affecting hair follicles.
Yutong Sun +3 more
doaj +1 more source
Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. [PDF]
, 2018 The myeloma bone marrow microenvironment promotes proliferation of malignant plasma cells and resistance to therapy. Activation of JAK/STAT signaling is thought to be a central component of these microenvironment-induced phenotypes.
Aftab, Blake T +13 more
core +2 more sources